June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Impact of Educational Intervention on Compliance with Topical Therapy for Glaucoma
Author Affiliations & Notes
  • Shani Reich
    Department of Ophthalmology, Bronx Lebanon Hospital, Bronx, NY
  • Justin Rome
    Department of Ophthalmology, Bronx Lebanon Hospital, Bronx, NY
  • Jack Manns
    Department of Ophthalmology, Bronx Lebanon Hospital, Bronx, NY
  • Lilly Droll
    Department of Ophthalmology, Bronx Lebanon Hospital, Bronx, NY
  • Joseph Zelefsky
    Department of Ophthalmology, Bronx Lebanon Hospital, Bronx, NY
    Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Bronx, NY
  • Footnotes
    Commercial Relationships Shani Reich, None; Justin Rome, None; Jack Manns, None; Lilly Droll, None; Joseph Zelefsky, Alcon (R), Allergan (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3517. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shani Reich, Justin Rome, Jack Manns, Lilly Droll, Joseph Zelefsky; Impact of Educational Intervention on Compliance with Topical Therapy for Glaucoma. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3517.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Poor compliance with medical therapy is a barrier for effective treatment of disease. Previous studies have shown increased compliance with medical therapy for glaucoma with educational interventions. While these predominantly focused on Caucasian and Black populations, data for the Hispanic community is limited. The goal of this study was to determine if educational intervention can increase compliance in patients on travoprost in the Hispanic population.

Methods: Patients with glaucoma or ocular hypertension on travoprost therapy were enrolled. Patients under 18 years of age, unable to self-administer drops, or using any other drops were excluded. Patients were provided with a Travatan Dosing Aid (TDA), an electronic device that records when a drop of travoprost is dispensed. At one-month follow-up the data was downloaded off of the TDA and compliance was calculated. Those with <75% compliance were randomized into either an education or control group. Patients in the education group watched a 10 minute video produced by the AAO, in either English or Spanish, discussing glaucoma and eye drop usage, followed by verbal reinforcement of drop usage. Control group patients were only given verbal reinforcement of drop usage. Compliance was reassessed 2 months later.

Results: A total of 70 patients will be enrolled; 44 patients are enrolled thus far, 10 of which are mid-study. Of the 34 who have completed the study to date (22 Hispanic, 12 Black), baseline compliance was 45% (40% Hispanics, 54% Blacks). Nine patients (4 Hispanic, 5 Black) had >75% compliance (mean 90%, range 78-100%), and 25 patients (18 Hispanic, 7 Black) had <75% compliance (mean 29%, range 4-70%) at one-month follow-up. Thirteen patients were randomized to the educational group, and 12 to the control group. Compliance rates in the education group were increased from 25%→46%, p=0.006, (23%→49%, p=0.009 in Hispanics, and 28%→45%, p=0.03 in Blacks) at the three-month follow-up. There was no statistically significant change in compliance in the control group (34%→36% overall, p=0.7; 37%→37%, p=0.99 in Hispanics, and 23%→32%, p=0.6, in Blacks).

Conclusions: Compliance with glaucoma therapy remains a major problem in glaucoma management. In our Hispanic and Black patient population, compliance increased with educational intervention. This study underscores the importance of education in increasing compliance with glaucoma therapy.

Keywords: 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×